中华皮肤科杂志 ›› 2026, e20250541.doi: 10.35541/cjd.20250541
• 指南与共识 • 上一篇
《西罗莫司治疗卡波西样血管内皮瘤中国专家共识（2026版）》制订专家组
收稿日期:2025-09-29
修回日期:2026-01-05
发布日期:2026-07-07
通讯作者:
李凯;吉毅
E-mail:likai2727@163.com; jijiyuanyuan@163.com
基金资助:Expert Group of the “Chinese expert consensus on sirolimus in the treatment of Kaposiform hemangioendothelioma （2026 edition）”
Received:2025-09-29
Revised:2026-01-05
Published:2026-07-07
Contact:
Li Kai; Ji Yi
E-mail:likai2727@163.com; jijiyuanyuan@163.com
Supported by:摘要： 【摘要】 卡波西样血管内皮瘤（KHE）是具有局部侵袭性的罕见血管源性肿瘤，可合并凝血功能障碍，导致弥散性血管内凝血而危及生命。目前最新的KHE诊疗共识将西罗莫司列为不可切除KHE的一线治疗药物，替代传统的糖皮质激素或长春新碱等，显著提高了患者的生存率及生活质量。为了加强西罗莫司临床应用的科学性与规范性，国内33位长期从事KHE诊治工作的各领域、各专业的资深专家结合我国临床实践情况，参照最新循证证据，达成一致推荐意见，制订《西罗莫司治疗卡波西样血管内皮瘤中国专家共识（2026版）》。
《西罗莫司治疗卡波西样血管内皮瘤中国专家共识（版）》制订专家组. 西罗莫司治疗卡波西样血管内皮瘤中国专家共识（2026版）[J]. 中华皮肤科杂志, 2026,e20250541. doi:10.35541/cjd.20250541
Expert Group of the “Chinese expert consensus on sirolimus in the treatment of Kaposiform hemangioendothelioma （ edition）”. Chinese expert consensus on sirolimus in the treatment of Kaposiform hemangioendothelioma （2026 edition）[J]. Chinese Journal of Dermatology,2026,e20250541. doi:10.35541/cjd.20250541
| ［1］ | Wassef M, Blei F, Adams D, et al. Vascular anomalies classification: recommendations from the International Society for the Study of Vascular Anomalies［J］. Pediatrics, 2015,136（1）:203⁃214. DOI: 10.1542/peds.2014⁃3673. |
| ［2］ | Zukerberg LR, Nickoloff BJ, Weiss SW. Kaposiform hemangioendothelioma of infancy and childhood. An aggressive neoplasm associated with Kasabach⁃Merritt syndrome and lymphangiomatosis［J］. Am J Surg Pathol, 1993,17（4）:321⁃328. DOI: 10.1097/00000478⁃199304000⁃00001. |
| ［3］ | Zhou J, Yang K, Dai S, et al. Clinical features and management of Kaposiform hemangioendothelioma and tufted angioma: similarities and differences［J］. J Am Acad Dermatol, 2022,87（1）:172⁃174. DOI: 10.1016/j.jaad.2021.07.012. |
| ［4］ | Nieto⁃Benito LM, Huerta⁃Aragonés J, Parra⁃Blanco V, et al. Kaposiform hemangioendothelioma and tufted angioma: two entities of the same clinicopathological spectrum［J］. An Bras Dermatol, 2023,98（3）:391⁃394. DOI: 10.1016/j.abd.2021.07.010. |
| ［5］ | 代诗懿, 杨开颖, 邱桐, 等. 卡波西样血管内皮瘤117例临床分析［J］. 中国皮肤性病学杂志, 2020,34（5）:542⁃549. DOI: 10.13735/j.cjdv.1001⁃7089.201908138. |
| ［6］ | 兰钰茹, 周江元, 邱桐, 等. 卡波西样血管内皮瘤来源内皮细胞的分离、纯化、鉴定、培养与表型分析［J］. 中华皮肤科杂志, 2025,58（5）:453⁃459. DOI: 10.35541/cjd.20240400. |
| ［7］ | Croteau SE, Liang MG, Kozakewich HP, et al. Kaposiform hemangioendothelioma: atypical features and risks of Kasabach⁃Merritt phenomenon in 107 referrals［J］. J Pediatr, 2013,162（1）:142⁃147. DOI: 10.1016/j.jpeds.2012.06.044. |
| ［8］ | Ji Y, Chen S, Yang K, et al. Kaposiform hemangioendothelioma: current knowledge and future perspectives［J］. Orphanet J Rare Dis, 2020,15（1）:39. DOI: 10.1186/s13023⁃020⁃1320⁃1. |
| ［9］ | Lim YH, Bacchiocchi A, Qiu J, et al. GNA14 somatic mutation causes congenital and sporadic vascular tumors by MAPK activation［J］. Am J Hum Genet, 2016,99（2）:443⁃450. DOI: 10.1016/j.ajhg.2016.06.010. |
| ［10］ | Hall GW. Kasabach⁃Merritt syndrome: pathogenesis and management［J］. Br J Haematol, 2001,112（4）:851⁃862. DOI: 10.1046/j.1365⁃2141.2001.02453.x. |
| ［11］ | 代诗懿, 彭素华, 陈思源, 等. 卡波西样血管内皮瘤的研究进展［J］. 临床小儿外科杂志, 2020,19（6）:544⁃547,553. |
| ［12］ | 陈辉, 林晓曦, 林梅绥, 等. 伴Kasabach⁃Merritt现象卡波西形血管内皮瘤和丛状血管瘤的临床及病理特征［J］. 中华皮肤科杂志, 2009,42（10）:674⁃676. DOI: 10.3760/cma.j.issn.0412⁃4030.2009.10.006. |
| ［13］ | O'Rafferty C, O'Regan GM, Irvine AD, et al. Recent advances in the pathobiology and management of Kasabach⁃Merritt phenomenon［J］. Br J Haematol, 2015,171（1）:38⁃51. DOI: 10.1111/bjh.13557. |
| ［14］ | Borst AJ, Eng W, Griffin M, et al. Treatment practices and response in Kaposiform hemangioendothelioma: a multicenter cohort study［J］. Pediatr Blood Cancer, 2024,71（3）:e30779. DOI: 10.1002/pbc.30779. |
| ［15］ | Liu X, Li J, Qu X, et al. Clinical outcomes for systemic corticosteroids versus vincristine in treating Kaposiform hemangioendothelioma and tufted angioma［J］. Medicine （Baltimore）, 2016,95（20）:e3431. DOI: 10.1097/MD.00000000 00003431. |
| ［16］ | Liu XH, Li JY, Qu XH, et al. Treatment of Kaposiform hemangioendothelioma and tufted angioma［J］. Int J Cancer, 2016,139（7）:1658⁃1666. DOI: 10.1002/ijc.30216. |
| ［17］ | Yao W, Li K, Wang Z, et al. Comparison of efficacy and safety of corticosteroid and vincristine in treating Kaposiform hemangioendothelioma and tufted angioma: a multicenter prospective randomized controlled clinical trial［J］. J Dermatol, 2021,48（5）:576⁃584. DOI: 10.1111/1346⁃8138.15767. |
| ［18］ | Li G, Hu Y, Li D, et al. Vincristine⁃induced peripheral neuropathy: a mini⁃review［J］. Neurotoxicology, 2020,81:161⁃171. DOI: 10.1016/j.neuro.2020.10.004. |
| ［19］ | Drolet BA, Trenor cc, brandão lr, et al. Consensus⁃derived practice standards plan for complicated Kaposiform hemangioendothelioma［J］. J Pediatr, 2013,163（1）:285⁃291. DOI: 10.1016/j.jpeds.2013.03.080. |
| ［20］ | Blatt J, Stavas J, Moats⁃Staats B, et al. Treatment of childhood Kaposiform hemangioendothelioma with sirolimus［J］. Pediatr Blood Cancer, 2010,55（7）:1396⁃1398. DOI: 10.1002/pbc.22766. |
| ［21］ | 杨家健. 西罗莫司治疗婴幼儿卡梅现象的研究进展［J］. 儿科药学杂志, 2019,25（6）:55⁃58. DOI: 10.13407/j.cnki.jpp.1672⁃108X.2019.06.018. |
| ［22］ | Wang J, Han Q, Yan H, et al. Overexpression Prox1 in HemECs resembles Kaposiform hemangioendothelioma and cytotoxicity of sirolimus in vitro［J］. J Pediatr Surg, 2021,56（7）:1203⁃1210. DOI: 10.1016/j.jpedsurg.2021.03.023. |
| ［23］ | Qiu T, Xiang S, Zhou J, et al. Sirolimus for Kaposiform hemangioendothelioma: potential mechanisms of action and resistance［J］. Int J Cancer, 2025,156（4）:689⁃699. DOI: 10. 1002/ijc.35207. |
| ［24］ | Peng S, Yang K, Xu Z, et al. Vincristine and sirolimus in the treatment of Kaposiform haemangioendothelioma［J］. J Paediatr Child Health, 2019,55（9）:1119⁃1124. DOI: 10.1111/jpc.14370. |
| ［25］ | Wang H, Duan Y, Gao Y, et al. Sirolimus for vincristine⁃resistant kasabach⁃merritt phenomenon: report of eight patients［J］. Pediatr Dermatol, 2017,34（3）:261⁃265. DOI: 10.1111/pde. 13077. |
| ［26］ | Ji Y, Chen S, Xiang B, et al. Sirolimus for the treatment of progressive Kaposiform hemangioendothelioma: a multicenter retrospective study［J］. Int J Cancer, 2017,141（4）:848⁃855. DOI: 10.1002/ijc.30775. |
| ［27］ | Zhou J, Li Y, Qiu T, et al. Long⁃term outcomes of sirolimus treatment for Kaposiform hemangioendothelioma: continuing successes and ongoing challenges［J］. Int J Cancer. 2023;153（3）:600⁃608. DOI: 10.1002/ijc.34509. |
| ［28］ | 何瑞, 张斌, 李丽, 等. 外用西罗莫司治疗儿童浅表脉管畸形19例的临床疗效及安全性分析［J］. 中华皮肤科杂志, 2022,55（2）:129⁃134. DOI: 10.35541/cjd.20210629. |
| ［29］ | 李云玲, 郑惠文, 李寅, 等. 西罗莫司联合普萘洛尔治疗婴儿蓝色橡皮疱痣综合征一例［J］. 中华皮肤科杂志, 2020,2020（7）:564⁃565. DOI: 10.35541/cjd.20190309. |
| ［30］ | 王跃生, 张敬, 李小芹, 等. 西罗莫司治疗儿童蓝色橡皮疱痣综合征1例［J］. 中华皮肤科杂志, 2022,55（9）:810⁃811. DOI: 10.35541/cjd.20200219. |
| ［31］ | 卡波西样血管内皮瘤诊疗专家共识小组. 卡波西样血管内皮瘤诊疗中国专家共识（2023）［J］. 中华小儿外科杂志, 2024,45（1）:1⁃9. DOI: 10.3760/cma.j.cn421158⁃20231019⁃00419. |
| ［32］ | Zhou J, Qiu T, Zhang Z, et al. Consensus statement for the diagnosis, treatment, and prognosis of Kaposiform hemangioendothelioma［J］. Int J Cancer, 2025,156（10）:1986⁃1994. DOI: 10.1002/ijc.35344. |
| ［33］ | Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations［J］. BMJ, 2008,336（7650）:924⁃926. DOI: 10.1136/bmj.39489.470347.AD. |
| ［34］ | Popova NV, Jücker M. The role of mTOR signaling as a therapeutic target in cancer［J］. Int J Mol Sci, 2021,22（4）:1743. DOI: 10.3390/ijms22041743. |
| ［35］ | Weyrich AS, Denis MM, Schwertz H, et al. mTOR⁃dependent synthesis of Bcl⁃3 controls the retraction of fibrin clots by activated human platelets［J］. Blood, 2007,109（5）:1975⁃1983. DOI: 10.1182/blood⁃2006⁃08⁃042192. |
| ［36］ | Wang L, Liu G, Wu N, et al. mTOR regulates GPVI⁃mediated platelet activation［J］. J Transl Med, 2021,19（1）:201. DOI: 10. 1186/s12967⁃021⁃02756⁃y. |
| ［37］ | Aslan JE, Tormoen GW, Loren CP, et al. S6K1 and mTOR regulate Rac1⁃driven platelet activation and aggregation［J］. Blood, 2011,118（11）:3129⁃3136. DOI: 10.1182/blood⁃2011⁃02⁃331579. |
| ［38］ | Cras TDL, Mobberley⁃Schuman PS, Broering M, et al. Angiopoietins as serum biomarkers for lymphatic anomalies［J］. Angiogenesis, 2017,20（1）:163⁃173. DOI: 10.1007/s10456⁃016⁃9537⁃2. |
| ［39］ | Conciatori F, Bazzichetto C, Falcone I, et al. Role of mTOR signaling in tumor microenvironment: an overview［J］. Int J Mol Sci, 2018,19（8）. DOI: 10.3390/ijms19082453. |
| ［40］ | Ji Y, Chen S, Li K, et al. Signaling pathways in the development of infantile hemangioma［J］. J Hematol Oncol, 2014,7:13. DOI: 10.1186/1756⁃8722⁃7⁃13. |
| ［41］ | Wang Z, Han Q, Wang J, et al. Rapamycin induces autophagy and apoptosis in Kaposiform hemangioendothelioma primary cells in vitro［J］. J Pediatr Surg, 2022,57（7）:1274⁃1280. DOI: 10.1016/j.jpedsurg.2022.02.032. |
| ［42］ | Li Y, Zhu X, Li L, et al. Construction and applications of the EOMA spheroid model of Kaposiform hemangioendothelioma［J］. J Biol Eng, 2024,18（1）:21. DOI: 10.1186/s13036⁃024⁃00417⁃4. |
| ［43］ | Zhang Y, Zhang C, Li L, et al. Lymphangiogenesis in renal fibrosis arises from macrophages via VEGF⁃C/VEGFR3⁃dependent autophagy and polarization［J］. Cell Death Dis, 2021,12（1）:109. DOI: 10.1038/s41419⁃020⁃03385⁃x. |
| ［44］ | Pei G, Yao Y, Yang Q, et al. Lymphangiogenesis in kidney and lymph node mediates renal inflammation and fibrosis［J］. Sci Adv, 2019,5（6）:eaaw5075. DOI: 10.1126/sciadv.aaw5075. |
| ［45］ | Ji Y, Yang K, Chen S, et al. Musculoskeletal complication in Kaposiform hemangioendothelioma without Kasabach⁃Merritt phenomenon: clinical characteristics and management［J］. Cancer Manag Res, 2018,10:3325⁃3331. DOI: 10.2147/CMAR.S171223. |
| ［46］ | 石浩强, 陈冰, 许倍铭. 西罗莫司药动学的影响因素及治疗药物监测［J］. 中国医药工业杂志, 2010,41（7）:543⁃547. |
| ［47］ | Wang D, Chen X, Li Z. Population pharmacokinetics of sirolimus in pediatric patients with Kaposiform hemangioendothelioma: a retrospective study［J］. Oncol Lett, 2019,18（3）:2412⁃2419. DOI: 10.3892/ol.2019.10562. |
| ［48］ | Johnson TN, Thomson M. Intestinal metabolism and transport of drugs in children: the effects of age and disease［J］. J Pediatr Gastroenterol Nutr, 2008,47（1）:3⁃10. DOI: 10.1097/MPG.0b0 13e31816a8cca. |
| ［49］ | Mizuno T, Fukuda T, Emoto C, et al. Developmental pharmacokinetics of sirolimus: implications for precision dosing in neonates and infants with complicated vascular anomalies［J］. Pediatr Blood Cancer, 2017,64（8）:26470. DOI: 10.1002/pbc.26470. |
| ［50］ | Fakhoury M, Litalien C, Medard Y, et al. Localization and mRNA expression of CYP3A and P⁃glycoprotein in human duodenum as a function of age［J］. Drug Metab Dispos, 2005,33（11）:1603⁃1607. DOI: 10.1124/dmd.105.005611. |
| ［51］ | Kahan BD, Napoli KL, Kelly PA, et al. Therapeutic drug monitoring of sirolimus: correlations with efficacy and toxicity［J］. Clin Transplant, 2000,14（2）:97⁃109. DOI: 10.1034/j.1399⁃0012.2000.140201.x. |
| ［52］ | Zhang J, Dai Y, Liu Z, et al. Effect of CYP3A4 and CYP3A5 genetic polymorphisms on the pharmacokinetics of sirolimus in healthy Chinese volunteers［J］. Ther Drug Monit, 2017,39（4）:406⁃411. DOI: 10.1097/FTD.0000000000000415. |
| ［53］ | McCune JS, Bemer MJ, Long⁃Boyle J. Pharmacokinetics, pharmacodynamics, and pharmacogenomics of immunosuppressants in allogeneic hematopoietic cell transplantation: partⅡ［J］. Clin Pharmacokinet, 2016,55（5）:551⁃593. DOI: 10.1007/s40262⁃015⁃0340⁃9. |
| ［54］ | Jimeno A, Rudek MA, Kulesza P, et al. Pharmacodynamic⁃guided modified continuous reassessment method⁃based, dose⁃finding study of rapamycin in adult patients with solid tumors［J］. J Clin Oncol, 2008,26（25）:4172⁃4179. DOI: 10.1200/JCO.2008.16.2347. |
| ［55］ | Jiao Z, Shi X, Li Z, et al. Population pharmacokinetics of sirolimus in de novo Chinese adult renal transplant patients［J］. Br J Clin Pharmacol, 2009,68（1）:47⁃60. DOI: 10.1111/j.1365⁃2125.2009.03392.x. |
| ［56］ | Kai L, Wang Z, Yao W, et al. Sirolimus, a promising treatment for refractory Kaposiform hemangioendothelioma［J］. J Cancer Res Clin Oncol, 2014,140（3）:471⁃476. DOI: 10.1007/s00432⁃013⁃1549⁃3. |
| ［57］ | Schmid I, Klenk AK, Sparber⁃Sauer M, et al. Kaposiform hemangioendothelioma in children: a benign vascular tumor with multiple treatment options［J］. World J Pediatr, 2018,14（4）:322⁃329. DOI: 10.1007/s12519⁃018⁃0171⁃5. |
| ［58］ | Ji Y, Chen S, Zhou J, et al. Sirolimus plus prednisolone vs sirolimus monotherapy for Kaposiform hemangioendothelioma: a randomized clinical trial［J］. Blood, 2022,139（11）:1619⁃1630. DOI: 10.1182/blood.2021014027. |
| ［59］ | Zhou J, Lan Y, Qiu T, et al. Efficacy and safety of high⁃ vs low⁃dose sirolimus in patients with Kaposiform hemangioendothelioma: a randomized clinical trial［J］. J Am Acad Dermatol, 2025,93（1）:124⁃131. DOI: 10.1016/j.jaad.2025.03.023. |
| ［60］ | Brill R, Uller W, Huf V, et al. Additive value of transarterial embolization to systemic sirolimus treatment in Kaposiform hemangioendothelioma［J］. Int J Cancer, 2021,148（9）:2345⁃2351. DOI: 10.1002/ijc.33406. |
| ［61］ | Shan Y, Tian R, Gao H, et al. Sirolimus for the treatment of Kaposiform hemangioendothelioma: in a trough level⁃dependent way［J］. J Dermatol, 2021,48（8）:1201⁃1209. DOI: 10.1111/1346⁃8138.15905. |
| ［62］ | Liu B, Zhang X, Zhao Y, et al. Model⁃informed individualized dosage regimen of sirolimus in pediatric patients with intractable lymphatic malformations［J］. Eur J Pharm Sci, 2024,200:106837. DOI: 10.1016/j.ejps.2024.106837. |
| ［63］ | Zimmerman JJ, Patat A, Parks V, et al. Pharmacokinetics of sirolimus （rapamycin） in subjects with severe hepatic impairment［J］. J Clin Pharmacol, 2008,48（3）:285⁃292. DOI: 10.1177/0091270007312902. |
| ［64］ | Ji Y, Yang K, Peng S, et al. Kaposiform haemangioendothelioma: clinical features, complications and risk factors for Kasabach⁃Merritt phenomenon［J］. Br J Dermatol, 2018,179（2）:457⁃463. DOI: 10.1111/bjd.16601. |
| ［65］ | Ettenger RB, Grimm EM. Safety and efficacy of TOR inhibitors in pediatric renal transplant recipients［J］. Am J Kidney Dis, 2001,38（4 Suppl 2）:22⁃28. DOI: 10.1053/ajkd.2001.27838. |
| ［66］ | Wang Z, Yao W, Sun H, et al. Sirolimus therapy for Kaposiform hemangioendothelioma with long⁃term follow⁃up［J］. J Dermatol, 2019,46（11）:956⁃961. DOI: 10.1111/1346⁃8138.15076. |
| ［67］ | Ji Y, Chen S, Yang K, et al. A prospective multicenter study of sirolimus for complicated vascular anomalies［J］. J Vasc Surg, 2021,74（5）:1673⁃1681. DOI: 10.1016/j.jvs.2021.04.071. |
| ［68］ | 周江元, 杨开颖, 彭素华, 等. 西罗莫司联合泼尼松治疗卡波西样血管内皮瘤伴Kasabach⁃Merritt现象初探［J］. 中华皮肤科杂志, 2020,（7）:514⁃518. DOI: 10.35541/cjd.20191172. |
| ［69］ | Yin C, Qi W, Wang S, et al. Efficacy of transcatheter arterial chemoembolization combined with sirolimus for treating Kasabach⁃Merritt phenomenon in infants, a retrospective study［J］. Ann Med, 2023,55（1）:2196090. DOI: 10.1080/07853890. 2023.2196090. |
| ［70］ | Thomas KV, Le T, Messele F, et al. Adding to your tool box: laser therapy for vascular anomalies［J］. Pediatr Dermatol, 2025,42（4）:716⁃727. DOI: 10.1111/pde.15991. |
| ［71］ | Zhang X, Yang K, Chen S, et al. Tacrolimus ointment for the treatment of superficial Kaposiform hemangioendothelioma and tufted angioma［J］. J Dermatol, 2019,46（10）:898⁃901. DOI: 10. 1111/1346⁃8138.15031. |
| ［72］ | Xiu B, Xu Z, Xu Z, et al. Additive therapeutic effects of topical sirolimus following oral propranolol therapy for Kaposiform hemangioendothelioma［J］. Clin Cosmet Investig Dermatol, 2025,18:1261⁃1267. DOI: 10.2147/CCID.S520410. |
| ［73］ | Wang Z, Li K, Yao W, et al. Steroid⁃resistant Kaposiform hemangioendothelioma: a retrospective study of 37 patients treated with vincristine and long⁃term follow⁃up［J］. Pediatr Blood Cancer, 2015,62（4）:577⁃580. DOI: 10.1002/pbc.25296. |
| ［74］ | Qiu T, Li Y, Gong X, et al. Oral antibiotic prophylaxis for infection in patients with vascular anomalies receiving sirolimus treatment: a multicenter retrospective study［J］. Orphanet J Rare Dis, 2023,18（1）:121. DOI: 10.1186/s13023⁃023⁃02740⁃3. |
| ［75］ | Zimmerman JJ, Ferron GM, Lim HK, et al. The effect of a high⁃fat meal on the oral bioavailability of the immunosuppressant sirolimus （rapamycin）［J］. J Clin Pharmacol, 1999,39（11）:1155⁃1161. |
| ［76］ | Deblon N, Bourgoin L, Veyrat⁃Durebex C, et al. Chronic mTOR inhibition by rapamycin induces muscle insulin resistance despite weight loss in rats［J］. Br J Pharmacol, 2012,165（7）:2325⁃2340. DOI: 10.1111/j.1476⁃5381.2011.01716.x. |
| ［77］ | Benet LZ, Cummins CL, Wu CY. Unmasking the dynamic interplay between efflux transporters and metabolic enzymes［J］. Int J Pharm, 2004,277（1⁃2）:3⁃9. DOI: 10.1016/j.ijpharm.2002. 12.002. |
| ［78］ | Paine MF, Leung LY, Lim HK, et al. Identification of a novel route of extraction of sirolimus in human small intestine: roles of metabolism and secretion［J］. J Pharmacol Exp Ther, 2002,301（1）:174⁃186. DOI: 10.1124/jpet.301.1.174. |
| ［79］ | Lown KS, Bailey DG, Fontana RJ, et al. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression［J］. J Clin Invest, 1997,99（10）:2545⁃2553. DOI: 10.1172/JCI119439. |
| ［80］ | Cohen EEW, Wu K, Hartford C, et al. Phase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patients［J］. Clin Cancer Res, 2012,18（17）:4785⁃4793. DOI: 10.1158/1078⁃0432.CCR⁃12⁃0110. |
| ［81］ | Worthy T, Jones A, Yang BE, et al. Effects of sirolimus on anti⁃SARS⁃CoV⁃2 vaccination in patients with lymphangioleiomyomatosis［J］. Chest, 2024,165（2）:303⁃306. DOI: 10.1016/j.chest.2023. 09.014. |
| ［82］ | Willcocks LC, Chaudhry AN, Smith JC, et al. The effect of sirolimus therapy on vaccine responses in transplant recipients［J］. Am J Transplant, 2007,7（8）:2006⁃2011. DOI: 10.1111/j.1600⁃6143.2007.01869.x. |
| ［83］ | Yuan J, Yuan Z, Ding Y, et al. Safety and immunogenicity of vaccines in children with Kaposiform hemangioendothelioma receiving sirolimus: a prospective study［J］. Vaccines （Basel）, 2025,13（9）:903. DOI: 10.3390/vaccines13090903. |
| ［84］ | Maruani A, Tavernier E, Boccara O, et al. Sirolimus （rapamycin） for slow⁃flow malformations in children: the observational⁃phase randomized clinical PERFORMUS trial［J］. JAMA Dermatol, 2021,157（11）:1289⁃1298. DOI: 10.1001/jamadermatol.2021.3459. |
| ［85］ | The Breast Cancer Expert Committee of the National Quality Control Center for Cancer, The Expert Committee on Cancer Prevention and Treatment of the Health China Research Center, The Society of Clinical Research on Oncology Medications of the China Anti⁃Cancer Association and The Society of Onco⁃Pathology of the China Anti⁃Cancer Association （2025）. Expert consensus on the clinical application of PI3K/AKT/mTOR inhibitors in the treatment of breast cancer （2025 edition）［J］. Cancer Innov. 2025,4（3）:e70008. DOI: 10.1002/cai2.70008. |
| ［86］ | Gulde A, Hasanov E, Krug K, et al. Everolimus⁃induced pneumonitis: a diagnostic challenge［J］. Breast J, 2020,26（2）:287⁃288. DOI: 10.1111/tbj.13554. |
| ［87］ | Peterson DE, Boers⁃Doets CB, Bensadoun RJ, et al. Management of oral and gastrointestinal mucosal injury: ESMO clinical practice guidelines for diagnosis, treatment, and follow⁃up［J］. Ann Oncol, 2015,26 Suppl 5:v139⁃151. DOI: 10.1093/annonc/mdv202. |
| ［88］ | Chambers MS, Rugo HS, Litton JK, et al. Stomatitis associated with mammalian target of rapamycin inhibition: a review of pathogenesis, prevention, treatment, and clinical implications for oral practice in metastatic breast cancer［J］. J Am Dent Assoc, 2018,149（4）:291⁃298. DOI: 10.1016/j.adaj.2017.10.024. |
| ［89］ | Hong JC, Kahan BD. Sirolimus⁃induced thrombocytopenia and leukopenia in renal transplant recipients: risk factors, incidence, progression, and management［J］. Transplantation, 2000,69（10）:2085⁃2090. DOI: 10.1097/00007890⁃200005270⁃00019. |
| ［90］ | Sun Q, Wu J, Chen X, et al. Efficacy and safety of sirolimus in the treatment of gastrointestinal angiodysplasias［J］. World J Gastroenterol, 2025,31（25）:105677. DOI: 10.3748/wjg.v31.i25. 105677. |
| ［91］ | Chen J, He W, Wang Y, et al. Long⁃term administration of sirolimus does not affect the physical development of children with tuberous sclerosis complex［J］. Childs Nerv Syst, 2022,38（5）:947⁃952. DOI: 10.1007/s00381⁃022⁃05446⁃2. |
| ［92］ | Pham PT, Pham PT, Danovitch GM, et al. Sirolimus⁃associated pulmonary toxicity［J］. Transplantation, 2004,77（8）:1215⁃1220. DOI: 10.1097/01.tp.0000118413.92211.b6. |
| ［93］ | Morath C, Schwenger V, Ksoll⁃Rudek D, et al. Four cases of sirolimus⁃associated interstitial pneumonitis: identification of risk factors［J］. Transplant Proc, 2007,39（1）:99⁃102. DOI: 10. 1016/j.transproceed.2006.10.219. |
| [1] | 魏瑾 闫会文 张建中 伦文辉. 司库奇尤单抗治疗合并人类免疫缺陷病毒感染的中重度斑块状银屑病10例临床疗效观察[J]. 中华皮肤科杂志, 2026, 59(7): 671-674. |
| [2] | 王琳琳 曹立娟 陈柳青 李东升 胡燕燕. 海姆泊芬光动力疗法治疗四肢鲜红斑痣疗效观察及安全性回顾分析[J]. 中华皮肤科杂志, 2026, 59(7): 637-644. |
| [3] | 刘怿菲 金炫沃 刘鹏月 张希萌 吴严. 点阵CO2激光联合A型肉毒毒素外用治疗面部毛孔粗大的半脸自身对照临床试验[J]. 中华皮肤科杂志, 2026, 59(7): 645-653. |
| [4] | 张国龙 赵子君. 氨基酮戊酸光动力疗法治疗皮肤鳞状细胞癌的现状、挑战和思考[J]. 中华皮肤科杂志, 2026, 59(7): 626-631. |
| [5] | 中国研究型医院学会皮肤科学专业委员会 中国医师协会皮肤科医师分会. [开放获取] 窄谱中波紫外线光疗皮肤科临床应用指南（2026版）[J]. 中华皮肤科杂志, 2026, 59(7): 595-610. |
| [6] | 中华医学会皮肤性病学分会光动力治疗研究协作组 中国康复医学会皮肤病康复专业委员会及光动力治疗与康复专业委员会 中国医学装备协会皮肤病与皮肤美容分会光医学治疗装备学组. 氨基酮戊酸光动力疗法治疗尖锐湿疣的临床应用指南（2026版）[J]. 中华皮肤科杂志, 2026, 59(7): 611-618. |
| [7] | 中华医学会皮肤性病学分会儿童皮肤病学组 中华医学会儿科学分会皮肤病学组 中国康复医学会皮肤病康复专业委员会儿童学组 中国康复医学会皮肤病康复专业委员会特应性皮炎学组 中国医师协会皮肤科医师分会儿童皮肤病学组 中国医师协会儿科学分会皮肤病学组. [开放获取] 中国儿童特应性皮炎预防、治疗与管理实践共识（2026版）[J]. 中华皮肤科杂志, 2026, 59(6): 487-504. |
| [8] | 李芳 林颖. 头颈部特应性皮炎的诊疗研究进展[J]. 中华皮肤科杂志, 2026, 59(6): 586-590. |
| [9] | 孙松朋 龙俊红 褚洪川 周阳洋 刘甲鑫 刘彦 霍兴霄 陈航 荆涛 高静 王艳逊 王锐 李振宇 张书信. 肤痔清软膏与曲安奈德益康唑乳膏治疗肛周慢性湿疹的临床疗效和安全性：一项多中心、随机、对照、双盲、等效性研究[J]. 中华皮肤科杂志, 2026, 59(6): 564-570. |
| [10] | 中国康复医学会皮肤病康复专业委员会 中国中西医结合学会皮肤性病专业委员会 . [开放获取] 老年银屑病诊疗与康复专家共识（2026版）[J]. 中华皮肤科杂志, 2026, 59(5): 407-418. |
| [11] | 中国康复医学会皮肤病康复专业委员会毛发疾病康复学组 北京整合医学学会毛发医学分会 中华医学会皮肤性病学分会毛发学组 国家皮肤与免疫疾病临床医学研究中心. 毛发活检病理中国专家共识（2026版）[J]. 中华皮肤科杂志, 2026, 59(5): 419-426. |
| [12] | 中华医学会皮肤性病学分会 中国医师协会皮肤科医师分会 中国医疗保健国际交流促进会皮肤医学分会 中国罕见病联盟皮肤病学分会. [开放获取] 肠道菌群移植治疗银屑病专家共识（2026版）[J]. 中华皮肤科杂志, 2026, 59(5): 427-435. |
| [13] | 张笑旭 罗素菊. 乌帕替尼治疗6例掌跖脓疱病的临床疗效与安全性分析[J]. 中华皮肤科杂志, 2026, 59(5): 459-463. |
| [14] | 中国“一带一路”皮肤病学专科联盟水疱病专病联盟 中华医学会皮肤性病学分会天疱疮/大疱性类天疱疮研究协作组. 抗p200类天疱疮诊断与治疗专家共识（2026版）[J]. 中华皮肤科杂志, 2026, 59(5): 387-395. |
| [15] | 中国妇幼保健协会儿童变态反应专业委员会儿童皮肤病学组. 儿童肛门生殖器硬化性苔藓诊疗管理中国专家共识（2026版）[J]. 中华皮肤科杂志, 2026, 59(5): 396-406. |
|
